Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is well-capitalized with a pro forma cash balance of $535 million and a fully funded development plan for their lead candidate pemvidutide, which has potential for peak annual revenues of over $5.0 billion. The company has successfully aligned with regulatory agencies and has upcoming catalysts for alcohol-related diseases with their Phase 2 trial for AUD data expected in 3Q26 and enrollment completion for their RESTORE trial in ALD, potentially pulling forward the next proof-of-concept milestone. Altimmune's operationalized PERFORMA trial design for pemvidutide in MASH shows potential for tolerability, simple titration, and quality weight loss. Additionally, Altimmune's potential to deliver quality weight loss with lean-mass preservation is a particularly relevant attribute for the projected average age at MASH diagnosis and the onset of clinically meaningful sarcopenia risk. Despite potential competition and clinical risks in the NASH and obesity markets, Altimmune's strong financial position and strategic approach make it a strong candidate for investment with a Buy rating.

Bears say

Altimmune is at risk due to its heavy reliance on the success of its key candidate, pemvidutide, in treating liver diseases which, if hindered by clinical or commercial challenges, would significantly impact the company's future outlook and stock price. Additionally, the company's limited institutional evaluation and need for future capital raises pose financial risks that may result in equity share dilution and negatively affect shareholder value. The company's Q4 2025 financial results also showed expenses exceeding estimates, raising concerns about efficient cash management and future profitability.

Altimmune (ALT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Altimmune (ALT) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.